Business Wire

HCL-GROUP

Share
HCL Group and UpLink Open Applications for its Third Global Aquapreneur Innovation Challenge

HCL Group, a global conglomerate, and UpLink, the open innovation platform of the World Economic Forum, announced the third challenge of the Aquapreneur Innovation Initiative, the “Tackling Water Pollution Challenge.” This announcement was made during the 10th World Water Forum in Bali, Indonesia. The application deadline for submission is 31st August 2024. The winners will be announced in January 2025, and the top 10 winners will receive a total financial award of 1.75M CHF. Detailed information and eligibility requirements can be accessed through the following link.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521731615/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sundar Mahalingam, President of Strategy at HCL Corporation, unveils Challenge 3 of the Aquapreneur Innovation Initiative at the World Water Forum in Bali (Photo: Business Wire)

Important Dates to Note

21 May to 31st August 2024

Open for submissions

1st September to 1st November 2024

Review and selection process

January 2025

Announcement of the Top Innovators

The Innovation Challenge aims to empower changemakers who are pioneering groundbreaking technologies, strategies, and approaches to conserve, manage, and protect water resources. HCL has pledged US$15 million over five years till 2027 to bolster entrepreneurs focusing on water-related endeavors. The challenge will focus on the intersection of the quality and environmental impacts of water, with the key aspects including:

  1. Preventing contamination of water at source- Source control aims to prevent or minimize the introduction of pollutants and contaminants at their source. Solutions may be aimed at contaminants from industry, agriculture, stormwater etc., and could include real-time monitoring and sensor networks, advanced filtration, and nature-based solutions.

  2. Monitoring and treating onsite industrial wastewater- Water is a core component in many industrial processes from manufacturing, cleaning and sanitation, mining, and cooling. Technological solutions offer a way to monitor water quality and reduce water contamination, minimize environmental impacts and move towards zero liquid discharge for industries.

  3. Optimising urban infrastructure public water and wastewater treatment systems- Water and wastewater treatment infrastructure upgrades are expensive and the costs are climbing. This area will target a broad range of technological solutions that can unlock value by improving efficiency, reducing costs, and ensuring compliance.

  4. Offering water quality solutions for households- The convergence of environmental awareness, cost considerations, regulatory pressures, and health concerns is driving the increasing popularity of personal water quality solutions among individuals and households. Technological solutions may include portable water testing, point-of-use water purification, and apps for crowd-sourcing water quality data.

While launching the challenge, Sundar Mahalingam, President of Strategy at HCL Corporation said, "At HCL, we understand the power of innovation, and through our partnership with UpLink, we are empowering Aquapreneurs to scale their solutions and drive meaningful impact. The first two editions of the Aquapreneur Innovation Initiative have demonstrated remarkable success, with participating entrepreneurs showcasing solutions that address critical water challenges. The Aquapreneurs from the first challenge have raised $54.5 million grants and venture capital funding since joining the cohort. This validates the effectiveness of the initiative in nurturing and supporting innovative ideas that address critical water challenges. We are, therefore, thrilled to announce the third challenge, aiming to engage a broader network of Aquapreneur globally.”

John Dutton, Head of UpLink, World Economic Forum, added, “At UpLink, we believe innovation and collaboration are key to overcoming the complex water challenges facing our planet. UpLink and HCL Group will tap into the world’s brightest entrepreneurial minds working in this sector to help minimize the problem of freshwater loss by connecting them to essential resources, experts, and funding. The Tackling Water Pollution Challenge will ensure that the most scalable solutions are deployed to ensure that this vital resource is sustainably available to all.

Evaluation and selection criteria for 3rd year includes:

  1. Business viability
    1. Demonstrates a financially sustainable business model with a clear revenue approach.
    2. Presents a funding history and potential for investment.
    3. Identifies and manages external risks effectively.
    4. Shows alignment with market demand locally or globally.
    5. Has a legal entity and operational plan for financial sustainability.

  2. Commitment to Deliver Impact
    1. Shows sustainable impact benefiting multiple sectors including society and the environment.
    2. Aligns with long-term water agenda goals.
    3. Utilizes a robust framework for impact measurement and verification.
    4. Transparently tracks metrics and adheres to relevant standards.

  3. Solution Novelty and Replicability
    1. Offers unique aspects in product/service, pricing, partnerships, or business model.
    2. Provides evidence of concept feasibility and replicability across different contexts.

As water scarcity and pollution continue to pose significant threats to communities and ecosystems globally, the Aquapreneur Innovation Initiative seeks to harness the power of innovation to create sustainable solutions. Selected participants will receive mentorship, funding support, access to networks, media visibility, and other resources to scale their initiatives and maximize their impact.

About HCL

Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978, well before its global peers. Today, the HCL enterprise has a presence across varied sectors that include technology, healthcare and talent management solutions and comprises three companies – HCL Infosystems, HCLTech and HCL Healthcare. The enterprise generates annual revenues of over US$13.3 billion with 227,481 employees operating across 60 countries. For further information, visit www.hcl.com

About UpLink

UpLink is the open innovation platform of the World Economic Forum, dedicated to unlocking an ‘entrepreneur revolution’ to support positive systemic change for people and planet. Launched at the Forum’s Annual Meeting in Davos in January 2020 with support from Salesforce and Deloitte, UpLink is now a thriving ecosystem of entrepreneurs, investors and experts, who are collaborating around innovation for the UN Sustainable Development Goals.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521731615/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye